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Genetic syndromes frequently present with overlapping clinical features and inconclusive or ambiguous genetic findings which can
confound accurate diagnosis and clinical management. An expanding number of genetic syndromes have been shown to have unique
genomic DNA methylation patterns (called ‘‘episignatures’’). Peripheral blood episignatures can be used for diagnostic testing as well as
for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes,
which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging patterns of overlap, as well as
similarities and hierarchical relationships across these episignatures, to highlight their key features as they are related to genetic hetero-
geneity, dosage effect, unaffected carrier status, and incomplete penetrance. We demonstrate the necessity of multiclass modeling for
accurate genetic variant classification and show how disease classification using a single episignature at a time can sometimes lead to
classification errors in closely related episignatures. We demonstrate the utility of this tool in resolving ambiguous clinical cases and
identification of previously undiagnosed cases through mass screening of a large cohort of subjects with developmental delays and
congenital anomalies. This study more than doubles the number of published syndromes with DNA methylation episignatures and,
most significantly, opens new avenues for accurate diagnosis and clinical assessment in individuals affected by these disorders.
Introduction
The past few years have seen the emergence of a critically
important development in the molecular diagnosis of
congenital disorders. DNA methylation episignatures,
defined as the cumulative DNA methylation patterns
occurring at multiple CpG dinucleotides across the
genome, have been recognized to be intricately associated
with many human traits, including age, sex, and disease
status.1–6 Specific patterns in the methylomes of individ-
uals with defined congenital syndromes have recently
received particular attention in clinical settings.7–9 The
elucidation of DNA methylation patterns in a range of
constitutional syndromes has led to the recognition that
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these episignatures represent an early event during embryo
development, and thus are present in numerous tissues of
the affected individuals, including peripheral blood, the
most common source of DNA specimens in diagnostic lab-
oratories.10,11 The stability of DNA methylation patterns
provides ground for their use in clinical diagnosis. The
conditions studied so far have demonstrated that the
observed episignatures are specific to the syndromes in
which they were discovered and that the observed patterns
occur consistently across all of the individuals affected
with the same syndrome;12 this promises that DNA
methylation episignatures have a great potential to unlock
the molecular diagnosis of congenital disorders, a feat
which frequently cannot be achieved by conventional
clinical and molecular assessments.13
We have previously been able to demonstrate that the
episignatures of genetic syndromes can be used to reliably
resolve ambiguous clinical cases associated with uncertain
sequence variant or clinical findings and to detect disease
through screening of cohorts of individuals with develop-
mental delay and congenital anomalies but without a
diagnosis.12–15,16,17 In April of 2019, the first clinical
genome-wide DNAmethylation assay, ‘‘EpiSign,’’ which uti-
lized genome-wide DNA methylation analysis for the
screening of 14 syndromes known to harbor such episigna-
tures, was launched. The computational assessment of DNA
methylation data for these syndromes relies on the concur-
rent assessment of all of the conditions through the use of
supervised and unsupervised classification algorithms; this
results in acceptable performance in the moderate number
of episignatures currently described.12,13 With an ongoing
study of new syndromes, however, the number of condi-
tions with episignatures to be included in the analysis will
rise significantly, and this will introduce challenges to our
current workflow. Specifically, the increased number of syn-
dromes will increase the chance of overlap across different
episignatures, and concurrent assessment of a large number
of episignatures requires the implementation of novel
computational approaches for disease classifications. To
date, these questions have not been addressed, and the chal-
lenges of concurrent assessment for a very large number of
DNA methylation episignatures are not known.
In the present study, we evaluate a large number of
congenital syndromes for DNA methylation patterns, and
we report 34 distinct and reliable episignatures. We demon-
strate the implementation of a uniform approach for map-
ping DNA methylation signatures in numerous syndromes
in order to enable their unbiased comparisons and assess-
ments. We discuss the overlap, similarity, and hierarchical
relationships across various episignatures, and we evaluate
the extent to which these parameters cause challenges in
episignature-based disease classification. Through the devel-
opment of a supervised classification algorithm capable of
simultaneous assessment of 34 episignatures, we demon-
strate that the classification of closely related episignatures
is feasible, and we show the power of this multiclass
approach in resolving undiagnosed individuals with various
forms of developmental delay and congenital anomalies.
Material and Methods
Subjects and Cohorts
The study cohort includes peripheral blood DNA samples from
individuals who each have a confirmed diagnosis of one of 42 ge-
netic syndromes (Table 1). These included samples collected from
the Greenwood Genetic Center (Greenwood, South Carolina,
USA), Amsterdam University Medical Center (Amsterdam,
Netherlands), Radboud University Medical Center (Nijmegen,
the Netherlands), Groupe DI France, Rouen University Hospital
(Rouen, France), Université Paris Diderot (Paris, France), McGill
University (Montreal, Canada), and Istituto di Ricovero e Cura a
Carattere Scientifico (Rome, Italy), as well as specimens described
in our previous publications.12,13,18–21 The a priori motive for the
selection of most of these syndromes was based on the involve-
ment of their associated genes in transcriptional and epigenetic
regulatory mechanisms and chromatin remodeling.22
Additional disease cohorts without established episignatures were
used to assess the specificity of the classificationmodels designed in
this study. These cohorts included individuals diagnosed with
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ADNP syndrome—50 and 30 terminal ends ADNP_T ADNP (outside
c.2000-2340)
615873 14 5 yes
ADNP syndrome—central ADNP_C ADNP
(c.2000-2340)
615873 10 3 yes
alpha-thalassemia mental retardation syndrome ATRX ATRX 301040 13 5 yes
autism, susceptibility to, 18 AUTS18a CHD8 615032 5 0 yes










Börjeson-Forssman-Lehmann syndrome BFLSa PHF6 301900 4 0 yes
cerebellar ataxia, deafness, and narcolepsy,
autosomal dominant
ADCADN DNMT1 604121 5 0 yes
CHARGE syndrome CHARGE CHD7 214800 45 15 yes
Chr7q11.23 duplication syndrome Dup7 Chr7q11.23
duplication
609757 8 2 yes
mental retardation, X-linked, syndromic,
Claes-Jensen type (Claes-Jensen syndrome)
CJS KDM5C 300534 26 8 yes





Down syndrome Down Chr21 trisomy 190685 29 10 yes
epileptic encephalopathy, childhood-onset EEOCa CHD2 615369 5 0 yes
Floating-Harbor syndrome FHS SRCAP 136140 15 5 yes
genitopatellar syndrome GTPTS KAT6B 606170 5 0 yes
Hunter McAlpine syndrome HMAa 17q23.1-q24.2
duplication
involving NSD1
601379 4 0 yes
immunodeficiency-centromeric instability-
facial anomalies syndrome 1
ICF1 DNMT3B 242860 8 0 yes
immunodeficiency-centromeric instability-






Kabuki syndrome 1 and 2 Kabukia KMT2D, KDM6Aa 147920, 300867 66 21 yes
Kleefstra syndrome 1 Kleefstra1a EHMT1 610253 15 5 yes
Koolen de Vreis syndrome KDVSa KANSL1 610443 6 0 yes
mental retardation, autosomal dominant 51 MRD51a KMT5B 617788 5 0 yes
mental retardation, X-linked 93 MRX93a BRWD3 300659 5 0 yes
mental retardation, X-linked 97 MRX97a ZNF711 300803 13 4 yes
mental retardation, X-linked syndromic,
Nascimento-type
MRXSNa UBE2A 300860 3 0 yes
mental retardation, X-linked, Snyder-
Robinson type
MRXSSRa SMS 309583 8 2 yes
Rahman syndrome RMNSa HIST1H1E 617537 6 0 yes
Rubinstein-Taybi syndrome 1 and 2 RSTSa CREBBP, EP300 180849, 613684 30 9 yes
SBBYSS syndrome SBBYSSa KAT6B 603736 7 0 yes
SETD1B-related syndrome SETD1Ba SETD1B N/A 8 0 yes
Sotos syndrome Sotos NSD1 117550 47 15 yes
Tatton-Brown-Rahman syndrome TBRSa DNMT3A 615879 10 4 yes
(Continued on next page)
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Angelman syndrome (MIM: 105830), Prader-Willi syndrome (MIM:
176270), Beckwith-Wiedemann syndrome (MIM: 130650), Coffin-
Lowry syndrome (MIM: 303600), Saethre-Chotzen syndrome
(MIM: 101400), Fragile X syndrome (MIM: 300624), Silver-Russell
syndrome (MIM: 180860), autism spectrum disorders, and RASopa-
thies which have also been described previously.12,13,18
The underlying genetic variant from each subject used in the
study was reviewed according to the American College of Medical
Genetics (ACMG) guidelines for interpretation of genomic
sequence variants,23 and only individuals confirmed to harbor
pathogenic or likely pathogenic variants together with the clinical
diagnosis were used to represent a syndrome.
Control specimens were healthy individuals without any devel-
opmental delay, intellectual disability, or congenital anomalies.
The first set of controls used for mapping of the episignatures
and training of the classification models included control speci-
mens from the reference control cohort in the London Health Sci-
ences Centre (LHSC) laboratory, along with additional control
samples from the centers listed above. Controls that were used
to measure the specificity of the developed classifier were
compiled from five large databases of general population samples
with various age and racial backgrounds.24–28
Unsolved cases that were screened in this study for the detection
of potentially affected individuals were collected from all of the
above sources over a period of four years. These samples were sup-
plemented with a publicly available DNA methylation cohort of
unresolved subjects that demonstrated various congenital anoma-
lies and developmental delays.29
DNA Methylation Experiment
Peripheral whole-blood DNA was extracted using standard
techniques. Following bisulfite conversion, DNA methylation
analysis of the samples was performed using the Illumina Infinium
methylation 450k or EPIC bead chip arrays according to the
manufacturer’s protocol. These arrays cover between 450,000
and 860,000 human genomic methylation CpG sites, including
99% of RefSeq genes and 96% of CpG islands. The resulting meth-
ylated and unmethylated signal intensity data were imported into
R 3.5.2 for analysis. Normalizationwas performed according to the
Illumina normalization method with background correction done
using the minfi package.30 Probes with detection p value > 0.01,
those located on chromosomes X and Y, those known to contain
a SNP at the CpG interrogation or single-nucleotide extension,
and probes known to cross-react with chromosomal locations
other than their target regions were removed. Arrays with more
than 5% failure probe rates were excluded from the analysis. The
methylation level for each probe was measured as a beta value,
which was calculated from the ratio of the methylated signals
versus the total sum of unmethylated and methylated signals,
ranging between 0 (no methylation) and 1 (full methylation).
All of the samples were examined for genome-wide methylation
density, and those deviating from a bimodal distribution were
excluded. Because samples were assayed using two different plat-
forms (450k and EPIC), following normalization and quality con-
trols, the downstream analyses were restricted to the probes shared
across the two array types in order to maintain consistency in the
computational workflow.
Selection of Cases and Matched Controls
We selected a random 75% subset of the affected subjects as a
training cohort for the purpose of mapping of DNA methylation
signatures and training of the classification models. The remain-
ing 25% was used as a testing dataset for the assessment of the
performance of the classification models developed later. All syn-
dromes and their subtypes were equally represented in both of
the training and testing cohorts. No division of the training and
testing cohorts was performed for conditions with sample sizes













Wiedemann-Steiner syndrome WDSTSa KMT2A 605130 12 4 yes
Williams syndrome Williams Chr7q11.23
deletion
194050 15 6 yes
Cornelia de Lange syndrome 5 (females only) CdLS5 HDAC8 300882 8 N/A no
FG syndrome 1 FG1a,b MED12 305450 9 N/A no
Glass syndrome Glassa,b SATB2 612313 9 N/A no
KMT2C-related syndrome» KMT2Ca,b,c KMT2C 617768 4 N/A no
neurodevelopmental disorder with coarse
facies and mild distal skeletal abnormalities
NEDCFSAa,b KDM6B 618505 5 N/A no
Rett syndrome Rett MECP2 312750 36 N/A no
Siderius-type X-linked syndromic mental
retardation
MRXSSDa,b PHF8 300263 9 N/A no
Smith-Magenis syndrome SMSa,b RAI1 309583 15 N/A no
aIndicates that these disorders (or some of their subtypes) were not evaluated in previous studies.
bIndicates cohorts with no evidence of a reproducible episignature; this is potentially due to small sample size. A possibility of an episignature is not completely
ruled out, and reanalysis using larger sample sizes is warranted.
cThe OMIM database, at the time of this study, has indicated that subjects with KMT2C mutations may be said to have ‘‘Kleefstra 2’’ syndrome. The DNA methyl-
ation signature found in Kleefstra 1 (caused by EHMT1), however, is completely absent in these subjects. It is acknowledged that these subjects have a distinct
phenotype from Kleefstra syndrome and a name change is currently in process with OMIM. The numbers in the testing and training cohort columns indicate
the sample counts available for each condition in each category. For cohorts with negative findings in the initial assessment, we did not further split the data
into testing and training, and thus, the values in the testing column are indicated with N/A (not applicable).
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a matched group of controls was selected through the use of the
MatchIt package. Matching was performed based on age, sex,
and the experimental batch. The sample size of the controls was
increased until both the matching quality and the sample size
were at their optimum and consistent across all diseases. This led
to the determination of a control sample size four times larger
than the case group in every comparison. Increasing the sample
size beyond this value impaired the matching quality. After each
matching trial, a principal component analysis (PCA) was per-
formed to detect outliers and examine the data structures. Outlier
samples and those with aberrant data structures were removed
before a second matching trial was conducted. The iteration was
repeated until no outlier sample was detected in the first two com-
ponents of the PCA.
Mapping of DNA Methylation Episignatures
DNA methylation studies commonly consider two factors for the
prioritization of CpG sites (probes, features, or predictors) that
are important in various conditions. These factors are the level
of methylation difference (effect size) and the probability that
the observed difference is a false positive (p value). Because micro-
array technology is not sensitive enough to detect very small de-
grees of methylation change when measuring the methylation
levels, and the number of tested CpGs is large, strict cut-offs are
applied to both p value and methylation difference estimations
during probe selection. In the literature, a range of cut-offs has
been used for minimum methylation differences (5%–20%) and
p values. The p value, specifically, can be varied based on the sam-
ple size and the confounding factors. In the current study, we have
assessed 42 different syndromes which are expected to have vary-
ing levels and extents of methylation change. As examples, from
our previous studies, we have observed that Sotos syndrome can
be associated with robust changes in tens of thousands of probes,
whereas this figure in Aref-Eshghi et al’s BAFopathies study hardly
reaches 500.12,18 Therefore, the determination of a universal cutoff
for methylation change and p value for all of the syndromes in the
current study might not be a practical approach. In order to
accommodate this level of heterogeneity across multiple condi-
tions, instead, we determined a set of ~150 probes to be the
most representative of the DNA methylation episignature for
each condition, in line with what we had observed in our previous
studies regarding the minimum number of probes needed for the
classification of different syndromes.13
The following workflow was performed for each condition sepa-
rately. We initially performed a multivariate linear regression
modeling using the limma package.31 The methylation levels
(beta value) were logit transformed into M-values (log2(beta/
(1-beta))) in order to ensure homoscedasticity for linear modeling.
The analysis was adjusted for blood cell type variations. The estima-
tionofbloodcellmixturewasperformedaccording to thealgorithm
developed by Houseman et al.32 The estimated values for each cell
component were incorporated into themodel matrix of the regres-
sionanalysis as confoundingvariables. In situationswhere the sam-
ples were assayed in multiple batches or multiple arrays, we also
adjusted the analysis for the top 10 principal components of the
selecteddata. Thepvalues obtained in linearmodelingweremoder-
ated using the eBayes function. To prioritize the best set of probes
for each analysis, we used the interaction between the effect size
and p value bymultiplying the absolutemethylation difference be-
tween theaffected subjects andcontrolsby thenegative valueof the
log-transformed p value (-log(p value)). The top 1,000 probes with
the greatest obtained valueswere selected. Next, we performed a re-
ceiver’s operating curve characteristics analysis for every probe and
measured the pairwise correlation coefficient between them.
Selection of 100–150 probes from this list was conducted by first
filtering out the half of the probes with the lowest area under the
curve (AUC) and then removing another half from the remaining
probes, which were highly correlated with each other. This was
done by measuring the Pearson’s correlation coefficients and was
carried out separately in cases and controls. The correlation coeffi-
cient cut-offs used for each condition were not constant because
they yielded different levels of correlations across the selected
probes, and thus we experimented with R-squared cutoffs <0.6–
0.8 in order to reach the desired number of probes.
The final probes selected for each disorder contained those that
were most differentiating, non-redundant, and not influenced by
random data structures. To determine the robustness of the iden-
tified probes, before each analysis, 10%–20% of samples from the
training cohort, depending on the sample size, were set aside and
not used for feature selection. After each analysis, the patterns
generated by the selected probes were compared between the
samples used for the analysis with those that were not. Hierarchi-
cal clustering analysis with a heatmap and multidimensional
scaling were used for this purpose. A robust episignature was ex-
pected to generate a similar pattern in both groups. In addition,
we evaluated the methylation patterns of the other samples from
the same experimental batch as the cases to rule out the possibil-
ity that the observed profile was related to the experimental
batch structure. Furthermore, each condition was expected to
present a unique profile significantly different from what was
observed in controls. This entire process was repeated until all
of the samples were used at least once during probe selection.
Failure to adhere to any of these principles resulted in the conclu-
sion that the identified probes were not reliable, and when that
happened, that condition was excluded from further analysis.
When a syndrome was caused by variation in multiple genes,
each subtype was initially analyzed individually. If the probes
specific to each subtype were not able to distinguish that subtype
from the others, we concluded that they have indistinguishable
profiles and thus treated them as one episignature.
Assessment of the Relationship between Episignatures
Probes co-occurring between every two episignatures were visual-
ized using a circos plot.33 Further pairwise analysis for any two
episignatures was performed using hierarchical clustering analysis
with a heatmap as well as multidimensional scaling using the
probes specific to each of the two pairs. We performed systematic
analysis to determine the distance and similarities and the hierar-
chical order of the episignatures in order to visualize all episigna-
tures in one dendrogram. For this analysis, we used all of the sig-
nificant probes from all episignatures. For each syndrome, we
aggregated the methylation levels of each probe by their median
values across all of the samples with that condition in order to
generate a reference methylome for that syndrome. The aggre-
gated values were then used in a hierarchical clustering analysis
to generate a dendrogram (Ward’s method on Euclidean
distance). The episignatures clustering together in major branches
of the dendrogram were further analyzed using a t-distributed
stochastic neighbor embedding (t-SNE) analysis to visualize their
degree of overlap and distinction. The analysis was performed us-
ing the Rtsne package according to the default parameters in order
to reduce the dimensions of the data to two.34 The default
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perplexity parameter in the package (perplexity ¼ 30) was used.
For clusters with very small sample sizes, however, the perplexity
parameter was reduced to the smallest value possible.
Construction of a Classification Algorithm for All of the
Episignatures
Concurrent classification of individuals using multiple signatures
can become a challenging task, potentially yielding inaccurate re-
sults as the data heterogeneity and the number of classes increase.
We have previously demonstrated that support vector machines
(SVMs), a class of supervised large margin classifiers, can provide
enough power for differentiating disease groups from the healthy
controls through the use of DNA methylation data, and that its
performance remains acceptable given the small number of sam-
ples in rare syndromes (as few as five in some instances) and the
relatively large number of predictors.12,13 Inherently, however,
SVMs are binary classifiers, and their use for multiclass classifica-
tion requires several modifications. The most common solutions
for multiclass SVMs include one-against-one and one-against-all
methods. In our previous studies, we have successfully imple-
mented the one-against-one method for up to 16 classes13 in
which every class is compared one by one with all other classes.
Therefore, for n classes, this method will construct n3 (n1)/2 in-
dividual binary classifiers, and the final classification is made
through a consensus reached by all of them. This approach can
become challenging and impractical when the number of classes
and predictors increases. For example, for 40 classes, 780 individ-
ual classifiers are needed, and this demands a great computational
power. In addition, classes with a smaller number of samples or a
milder DNA methylation change will yield less confident classifi-
cations. As the cumulative number of the predictors (probes) in-
creases, the signal provided by such samples becomes diluted,
and the classifications become less accurate. In these scenarios,
the confidence scores generated for various disorders will be high-
ly variable, making the one-against-one SVM less optimal for use
in the clinical setting and diagnostic decision making. Therefore,
in this study, we attempted to use the one-against-all SVM. For n
classes, this method generates n1 individual binary classifiers,
each trained to distinguish the members of one class from the
combined members of all of the remaining diseases and controls.
This method significantly reduced the computational time and
made it feasible to scale it up to a large number of classes.
The training of each SVM classifier was performed with a linear
kernel using the e1071 R package. The training was only per-
formed on the training data subset. To determine the best hyper-
parameter to be used in linear SVM (cost), and to measure the ac-
curacy of the models, 10-fold cross-validation was performed
during the training of each classifier. In this process, the training
set was randomly divided into ten folds. Nine folds were used
for training the model and one fold was used for testing. After
we repeated this iteration for all of the ten folds, we calculated
the mean accuracy and selected the hyperparameters with the
most optimal performance. For every sample, the models were
set to generate a score ranging between 0 and 1, representing
the confidence of prediction for the specific class the SVM was
trained to detect. Conversion of SVM decision values to these
scores was carried out according to the Platt’s scaling method.35
A classification as one of the disorders was made when a sample
received the greatest score for that class, a score that also needed
to be greater than 0.5. The final models were applied to the
training dataset in order to ensure the success of the training.
We ensured that the constructed models were not sensitive to
the experimental batch structure of the methylation data by
applying this structure to all of the samples assayed on the same
batch that cases in the training dataset were drawn from. To
confirm that the classifiers were not sensitive to the blood cell
type compositions, we used methylation data from isolated blood
cell populations of healthy individuals36 and supplied them to our
models for prediction in order to examine the degree to which the
resulting scores were varied across different blood cell types. Next,
the models were applied to the testing cohort (25% subset of the
affected cases not used for feature selection or training) in order
to evaluate the predictive ability of the models on affected sub-
jects. To determine the specificity of the models, we supplied a
large number of DNA methylation arrays from healthy subjects.
To understandwhether themodels were sensitive to other congen-
ital disorders, we tested a large number of subjects with clinical
and molecular diagnoses of such syndromes confirmed by the
models.
Screening of Undiagnosed Subjects and Classification of
Uncertain Cases
The final algorithm was used to classify subjects suspected of hav-
ing any of the conditions used in the training, including those
with no sequence variant information available, with inconclusive
clinical assessment, or with DNA sequence variants of unknown
significance (VUS). In addition, we used the algorithm to screen
among a large group of individuals with various presentations of
developmental delays and congenital anomalies but who had no
established diagnosis despite routine clinical andmolecular assess-
ments including microarray copy-number variant (CNV) testing
or exome sequencing. The subjects who were predicted to have
the syndromes above were evaluated based on the available clin-
ical and molecular information.
Data Availability
Some of the datasets used in this study are available publically
and may be obtained from gene expression omnibus (GEO)
using the following accession numbers. GEO: GSE116992,
GSE66552, GSE74432, GSE97362, GSE116300, GSE95040, GSE
104451, GSE125367, GSE55491, GSE108423, GSE116300, GSE
89353, GSE52588, GSE42861, GSE85210, GSE87571, GSE87648,
GSE99863, and GSE35069. These include DNA methylation data
from patients with Kabuki syndrome, Sotos syndrome, CHARGE
syndrome, immunodeficiency-centromeric instability-facial anom-
alies (ICF) syndrome, Williams syndrome, Chr7q11.23 duplication
syndrome, Silver Russell syndrome, BAFopathies, Down syndrome,
a large cohort of unresolved subjects with developmental delays
and congenital abnormalities, and also several large cohorts of
DNA methylation data from the general population. The rest of
the data are not available due to the restrictions of the ethics
approval.
Ethics Statement
The study protocol has been approved by the Western University
Research Ethics Board (REB 106302) and the McMaster University
Hamilton Integrated Research Ethics Boards (REB 13-653-T).
Where applicable, participants provided informed consent prior
to sample collection. All of the samples and records were de-iden-
tified before any experimental or analytical procedures were
performed. The research was conducted in accordance with all
relevant ethical regulations.
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Results
Assessment of DNA Methylation Signatures in 42
Congenital Disorders
This study included peripheral blood DNA samples from a
total of 787 subjects affected by 42 syndromes and their
various subtypes. The syndrome names, their abbrevia-
tions, associated genes, OMIM identifiers, and the sample
sizes are summarized in Table 1. Following genome-wide
DNAmethylation analysis using Infinium arrays and qual-
ity controls, ~400,000 probes passed detection quality fil-
ters in at least 95% of the samples, and these probes were
used for subsequent analysis. Through the comparison of
the training subset (Table 1 and Table S1) with age- and
sex-matched samples selected from a pool of healthy con-
trols (n ¼ 749) for every condition, we prioritized between
100 and150 probes for each of their respective DNA
methylation signatures. Of the conditions tested, eight
did not have evidence of a reliable and replicable DNA
methylation signature and were excluded from further
assessment (Table 1), reducing the total training and
testing cohort sample sizes to 540 and 152, respectively





















Lack of separa on between Kabuki subtypes
Opposite pa erns between Sotos and HMA
Figure 1. Relationships across Various
Syndromes and Their Subtypes
The plot shows clustering analysis with
heatmap using probes specific to the
DNA methylation of one syndrome (or its
subtype) as compared with another. Rows
indicate probes and columns indicate sam-
ples. The top pane colors indicate the clas-
ses. The heatmap color scale from gold to
red represents the level of methylation
from 0–1.
(A) Probes differentially methylated in
Kabuki 1 (KMT2D) and controls do not
provide distinction between subjects with
Kabuki 1 and Kabuki 2 (KDM6A), although
they differentiate both of them from the
controls.
(B) The same pattern is observed when
Kabuki-2-specific probes are used.
(C) Probes differentially methylated be-
tween individuals with Hunter McAlpine
syndrome (HMA) (harboring duplication
ofNSD1) and controls generate a hyperme-
thylation pattern in the HMA individuals.
The same probes generate a mirror hypo-
methylation pattern in individuals with
Sotos syndrome (loss of function ofNSD1).
(D) The same mirror effect is observed
when probes selected for Sotos syndrome
are used.
selected probes to 3,643 (Tables S2
and S3). The extent of DNA methyl-
ation changes varied across different
conditions; Sotos syndrome; ICF syn-
drome; Tatton-Brown-Rahman syn-
drome (TBRS); mental retardation,
X-linked syndromic, nascimento-
type (MRXSN) syndrome; and autosomal dominant cere-
bellar ataxia, deafness, and narcolepsy (ADCADN) showed
the most robust methylation changes (methylation differ-
ences of up to 60% between the cases and controls). BAFo-
pathies, Cornelia de Lange syndrome (CdLS), Rubinstein-
Taybi syndrome (RSTS), and mental retardation X-linked
97 (MRX97) presented some of the mildest DNA methyl-
ation patterns (with maximum DNA methylation differ-
ence between the cases and controls not greater than 20%).
As a general trend, we observed that different subtypes of
the syndromes that result from multiple gene defects have
highly similar DNA methylation profiles. This was found
in Kabuki syndrome (Kabuki 1 and Kabuki 2), BAFopathies
(CSS1, CSS2, CSS3, CSS4, and NCBRS), Cornelia de Lange
syndrome (CdLS1, CdLS2, CdLS3, and CdLS4), and RSTS
(RSTS1 and RSTS2), in which probes selected in each sub-
type generated a similar pattern in the other subtypes
(Figure 1). Therefore, multiple subtypes of each of these
syndromes were treated as a single entity in further ana-
lyses. The only exception to this rule was found for ICF
syndrome. Despite a very robust shared DNA methylation
pattern in the four ICF subtypes, it was observed that ICF1
could be fully distinguished from the other three ICF
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subtypes (ICF2, ICF 3, and ICF 4),19 and thus ICF syndrome
type 1 and types 2–4 were treated as two separate episigna-
ture entities for the remainder of the study. One other
exception was noted in CdLS5, resulting from mutations
in HDAC8 for which no DNA methylation changes were
observed, likely due to skewed inactivation of the mutated
chromosome X in the peripheral blood of these individuals
(all were females in our cohort).37
Each of the genes studied here was found to be associ-
ated with a single DNA methylation signature with the
exceptions of ADNP and KAT6B. KAT6B mutations result
in two syndromes, genitopatellar syndrome (GTPTS) and
Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS),
each harboring a distinct DNA methylation signature.
The patterns in GTPTS were found to be more robust
than, and independent from, what was found in SBBYSS.
ADNP was the only example of a syndrome caused by mu-
tations in one gene but with two distinct DNAmethylation
signatures. The two signatures were distinguished by the
mutation coordinates within ADNP: subjects who
harbored variants within the central domain of c.2000–
2340 (ADNP central–ADNP_C) showed a distinct pattern
from those whose mutations resided in the regions outside
c.2000–2340 (ADNP terminal–ADNP_T). These two groups
were also treated as separate categories throughout
the study, yielding a total of 34 episignatures in this
manuscript.
In addition to the affected subjects, this study also in-
cludes apparently healthy individuals carrying pathogenic
mutations in four genes: KDM5C (X-linked recessive, 14
















Sotos-specific probes ATRX-specific probes
Kabuki-specific probes BAFopathy-specific probes
Figure 2. DNA Methylation Episignature
of One Syndrome in Others
The top two dimensions of multidimen-
sional scaling plots (x axis ¼ dim1,
y axis ¼ dim2) representing the pairwise
distance across the samples with various
episignatures:
(A) Sotos-syndrome-specific probes distin-
guish Sotos syndrome samples from con-
trols, but they do not differentiate alpha-
thalassemia mental retardation syndrome
(ATRX) samples from the controls.
(B) ATRX-specific probes differentiate both
Sotos syndrome and ATRX samples both
from controls and from each other.
(C) Kabuki-syndrome-specific probes differ-
entiate Kabuki syndrome samples from
controls, but they do not distinguish the
BAFopathy samples from controls.
(D) BAFopathy-specific probes generate an
intermediate pattern for the Kabuki syn-
drome subjects between the BAFopathies
and controls.
with incomplete penetrance, two
healthy carriers), BRWD3 (X-linked
recessive, one obligate female carrier),
and UBE2A (X-linked recessive, six
obligate female carriers). The key
observation here was that healthy carriers may also present
episignatures. The female KDM5C mutation carriers
showed an intermediate pattern between the affected
males and controls. Half of the KDM5C protein in the car-
rier females originates from the wild-type allele (KDM5C is
not subject to X-linked inactivation). The single female
carrier of a BRWD3 mutation also showed an intermediate
methylation pattern between the affected males and con-
trols. Despite an incomplete penetrance, the two healthy
individuals with heterozygous KMT5B mutations demon-
strated a methylation pattern similar to those of the
affected cases (also heterozygous). The obligate female
carriers of UBE2A, however, did not show any methyl-
ation changes, possibly due to skewed X chromosome
inactivation.38
Relationship between Different DNA Methylation
Signatures
The number of probes co-occurring at the episignatures of
any two conditions was very small (<5%, Figure S1). How-
ever, pairwise analysis of the methylation patterns showed
evidence of a relationship between some of them. We first
evaluated syndromes arising from alternative dosage in
shared genetic loci (i.e., loss of function versus gain of
function). Two examples of such conditions in our cohort
were Sotos syndrome versus Hunter McAlpine (HMA) syn-
drome (NSD1 loss of function versus NSD1 duplication,
respectively) and Williams syndrome versus Chr7q11.23
duplication syndrome (Chr7q11.23 deletion versus dupli-
cation). In both sets of these pairs, symmetrical DNA
methylation patterns were observed. This phenomenon
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was particularly striking in Sotos syndrome versus HMA
syndrome; the former is drastically hypomethylated
while the latter is distinctly hypermethylated (Figure 1).
Another such example was noted in a single subject with
duplication of ARID1A, which showed a mirrored DNA
methylation pattern of all other BAFopathies resulting
from loss-of-function mutations in the BAF complex genes
including ARID1A. A common observation that was found
in the pairwise comparisons of all syndromes was that in
syndromes with extensive methylation changes, the pat-
terns do not remain restricted to the probes selected for
those conditions, and they also occur in probes specific
to others. However, in any pairwise comparison, the
probes from one syndrome alone may or may not fully
distinguish the two syndromes from each other. Two ex-
amples of this phenomenon, one for a fully distinguish-
able pair (alpha-thalassemia mental retardation syndrome
[ATRX] and Sotos syndrome) and one for a poorly distin-
guishable pair (Kabuki syndrome and BAFopathies) are
illustrated in Figure 2. To systematically evaluate the rela-
tionship across all of the episignatures, we combined all
of the identified probes and performed a clustering analysis
to demonstrate the hierarchical order, as well as the simi-
larities among various conditions, based on their DNA
methylation profiles (Figure 3). The analysis generated
two main clusters. The first was composed of syndromes
with hypomethylation as the main pattern, including
Sotos syndrome, ICF syndrome, Rahman syndrome
(RMNS), Borjeson-Forssman-Lehmann syndrome (BFLS),
and TBRS, which are also clinically related to each other
in that growth abnormalities are major features they share.
The other branch was subdivided into three subclusters.
The smallest of these subclusters was composed of three
syndromes: HMA syndrome, MRXSN syndrome, and
SETD1B-related disorder, all with predominantly hyperme-
thylated profiles, clustering together in the greatest dis-
tance from the hypomethylated episignatures. The other
two clusters were composed of syndromes with mild-to-
moderate DNA methylation patterns. Some of these,
such as ATRX/ADNP_T or RSTS/CdLS generated pairs at
the terminal branches of the dendrogram, indicating their
high level of similarity. Of interest, the pair of Kabuki/
BAFopathy, which was discussed earlier, clustered very
close to each other. BAFopathies, specifically, had the
most similar DNA methylation pattern to controls, clus-
tering with them in a single branch.We projected the com-
bined DNAmethylation data of all of the probes from sam-
ples belonging to the major clusters identified here into
three two-dimensional plots (Figure 4). This analysis indi-
cated that despite similarities across some of these epis-
ignatures, they remain relatively distinct from each other
when all of the selected probes are taken into account.
Challenge of Disease Classification Using 34
Episignatures
Binary classification of disease versus control using one
episignature at a time is the most commonly used
approach for determining if an individual is affected by a
syndrome. Recognizing the considerable similarities
among some of the 34 episignatures described in this
study, we attempted to establish the accuracy of this
approach. We examined the syndromes that are most
closely related to each other as determined by using the
dendrogram in Figure 3. Among these, we found several
pairs, including RMNS/BFLS, MRXSN/SETD1B, Kabuki/
BAFopathy, and RSTS/CdLS, for which an effort at classifi-
cation using the episignature of only one pair was not al-
ways successful. An example of the workflow and the chal-
lenge is illustrated in Figure 5. The probes specific to RSTS
generate a clear separation between the RSTS subjects and
controls as demonstrated through the use of multidimen-
sional scaling (Figure 5A). We added three subjects with
uncertain diagnoses to this plot, one with a clinical diag-
nosis of RSTS but negative sequence finding in the RSTS-
related genes, one with a de novo VUS in the RSTS2-related
gene, EP300 (RefSeq accession number NM_001429.3,
c.4232C>T; RefSeq NP_001420.2, p.Thr1411Ile), and the
last subject with a rare variant in a CdLS-related
gene, SMC1A (RefSeq NM_006306.2, c.92T>C; RefSeq
NP_006297.2(LRG_773p2), p.Ile31Thr). Among the two
RSTS-suspected subjects, the first one clustered with all
confirmed RSTS cases, whereas the subject with EP300
VUS showed a pattern most similar to that of the controls
(Figure 5A); this result indicates that the first individual
was affected by RSTS, while the second was not. However,
it was also noted that the subject with the SMC1A variant is
situated closer to the RSTS subjects than to controls






























































































































Figure 3. Distance and Hierarchical Orders across 34 Episigna-
tures
The dendrogram shows the distance and hierarchical orders of
34 episignatures. The y axis is the measure of distance or dissim-
ilarity of either individual data points or clusters. The vertical
position of the split in the dendrogram indicates the distance be-
tween every two points or clusters. The major splits are shown in
different colors. Syndromes with very strong hypomethylation
patterns are clustered together on the right, whereas those with
hypermethylation episignatures are placed in a great distance
to those in the left. As seen, BAFopathies are the most similar
episignature to the controls, being consistent with their very
mild DNA methylation changes.
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subject was affected by RSTS or this classification was
incorrect due to the overlapping nature of the RSTS and
CdLS episignatures. To investigate this, we first added the
known cases of CdLS to this analysis, which variably clus-
tered with both controls and RSTS subjects (Figure 5B),
confirming that the episignature of RSTS partially overlap-
ped with that of CdLS. Repeating this analysis using probes
from both episignatures, however, completely separated
the two disorders from each other as well as from controls
(Figure 5C). This analysis now clusters the subject with the
SMC1A variant with other CdLS cases, indicating that the
initial classification was not correct. This example indi-
cates how attempts to classify disease by assessing one dis-
order at a timewithout the consideration of other episigna-
tures can be error-prone.
Development of a Classification Algorithm for the
Concurrent Detection of 34 Episignatures
Concurrent assessment of multiple syndromes through
the use of unsupervised analysis can become challenging
and inaccurate when the number of classes increases to
the scale presented in this manuscript. A supervised anal-
ysis may provide a more robust solution in these situa-
tions. We developed 34 individual SVM classifiers for the
episignatures in this study, each trained to distinguish
one disease class from the controls and also from the other
33 episignatures. The models were set to generate 34 scores
ranging from 0–1, with higher scores representing a greater
chance for any given subject of having a DNAmethylation
profile similar to each of the episignatures, respectively.
The training was performed on the training cohort, during
which 10-fold cross-validation was performed, resulting in
an average accuracy of 99.9%. To control for the success of
the procedure, the entire training cohort was supplied to
the final models, which assigned correct classifications to
all of the cases and controls used for training. Every sample
was correctly classified into the category it belonged to, ob-
taining scores significantly greater from the other classes
(Figure 6). We also confirmed that the classifiers were not
sensitive to the batch structure of the data. To do this, we
applied the classifiers to other samples processed in the
same batch as the cases. All of these other samples received
very low scores for all of the 34 classes. Additionally, we
evaluated the extent to which the variation in blood cell
type compositions influenced the scores. We did this by
applying the classifiers to a total of 60 methylation array
data files from six healthy individuals, each being assayed
separately for whole blood, peripheral blood mononuclear
cells, and granulocytes, as well as for seven isolated cell





































Figure 4. Dimensionality Reduction of DNA Methylation Data
from 34 Peripheral Blood DNA Methylation Episignatures
The members of the three major clusters identified in the dendro-
gram in Figure 3 were projected in three separate two-dimensional
plots (A–C) using a t-distributed stochastic neighbor embedding
(t-SNE). Despite similarities observed across some, the use of all
of the probes from all episignatures together provides enough dis-
tinctions between them. A small subgrouping is observed for
BAFopathies and CHARGE syndrome. This observation is not ex-
plained by the genes involved, mutation coordinates, mutation
type, clinical presentations, age, or sex. It is also not replicated
when probes specific to each of these conditions are used for
this analysis.
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and CD14þ monocytes, neutrophils, and eosinophils). All
of these samples received very low scores (<0.05) for all of
the 34 classes and showed <5% average inter-cell-type
variability in the scores.
We next applied the model to the entire testing cohort,
which was composed of 152 samples that were not used
for feature selection or model training. All of these samples
were assigned the expected class with scores similar to
those of the training dataset; these results confirm that
the models were robust in disease classification (Figure 6).
To measure the specificity of our classifier, we tested whole
blood methylation data from a total of 2,315 healthy sub-
jects of various ethnic backgrounds (aged 0–94); all of this
data received very low scores for all of the 34 episignatures
(Figure 6). We also questioned whether the model could
differentiate the above syndromes from other congenital
or Mendelian disorders not included in the training
cohort. The DNAmethylation profiles of a total of 442 sub-
jects, diagnosed with these types of syndromic conditions,
were supplied to the algorithm for classification; and all
of these profiles scored very low for all of the 34 categories
(Figure 6), further confirming the specificity of our
algorithm.
Screening of Unresolved Cohort and Classification of
Uncertain Cases
We have previously demonstrated that individuals with
neurodevelopmental syndromes lacking a diagnosis may
be identified and diagnosed through screening of their
DNA methylation profiles. Here, we tested two previously
described cohorts of such individuals13 who have various
developmental disorders and who have remained unre-
solved following the routine clinical assessments. This
included 965 subjects, the majority of whom had under-
gone CNVmicroarray testing as part of the standard clinical
workup, along with additional genetic testing in some
cases, including targeted gene/panel or exome sequencing.
These individuals had various forms of neurodevelopmen-
tal delays and congenital anomalies, including facial
dysmorphism, developmental delay and/or intellectual
disability, degenerative neural disease, autism, and various
congenital organ defects, though none were suspected to
have any of the syndromes described in this study.
Applying our classifier to this cohort allowed the identifica-
tion of nine subjects matching some of the newly described
episignatures. This included the detection of three subjects
with Wiedemann-Steiner syndrome (WDSTS), two subjects
with TBRS, and four others with Kleefstra syndrome, RMNS,
Koolen-de Vries syndrome (KDVS), and Epileptic encepha-
lopathy, childhood-onset (EEOC), respectively (Figure 6
and Table S4). Most of these individuals were not available
for further assessment; however, their reported clinical
Figure 5. The Challenge of Disease Classification Using Closely
Related Episignatures
The plot shows an attempt at disease classification of three
subjects using DNA methylation data through unsupervised
analysis.
(A) Multidimensional scaling of DNA methylation data from
probes specific to RSTS episignature provides enough distinction
between the Rubinstein-Taybi syndrome (RSTS) subjects and
controls. The addition of two samples from individuals sus-
pected to have RSTS (purple) clusters one of them with controls
and the other with RSTS subjects. Another sample from an indi-
vidual suspected to have Cornelia de Lange syndrome (CdLS;
orange), however, is also situated closer to RSTS subjects than
to controls.
(B) The addition of the CdLS samples to the analysis using the
RSTS-specific probes demonstrates that these samples show an in-
termediate pattern between RSTS and controls.
(C) Incorporation of probes specific to CdLS in the analysis dem-
onstrates that CdLS subjects are indeed distinct from RSTS cases.
The uncertain sample from the individual suspected of having
CdLS now clearly clusters with the other confirmed CdLS subjects.
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features were consistent with their predicted syndromes
(Table S4). These features included macrosomia and macro-
cephaly in a TBRS-predicted individual, myoclonic seizures
and behavioral problems in an EEOC-predicted individual,
and speech problem with a bicuspid aortic valve in a KDVS-
predicted individual. The subject presenting with the
methylation profile of Kleefstra syndrome was initially re-
ported to have an Angelman-like phenotype. An ultimate
diagnosis for many such cases is Kleefstra syndrome.39
Of interest, the subsequent DNA sequencing identified
a heterozygous splice site variant in EHMT1 (RefSeq
NM_024757.4, c.3540þ1G>C; RefSeq NP_079033.4, p.?),
confirming our prediction. Another subject in this study
who had amethylation profile similar to RMNSwas the sec-
ond case whose prediction was confirmed through
sequencing. He was a two-year-old male presenting with
developmental delay, hypotonia, abnormal brain MRI
findings (ventriculomegaly), and cryptorchidism. The
RMNS phenotype is highly variable and these findings
can be observed in numerous syndromes. The genome
sequencing, however, identified a de novo frameshift variant
in HIST1H1E (RefSeq NM_005321.2, c.436_458del, RefSeq
NP_005312.1, p.Thr146AspfsTer42), confirming the diag-
nosis of RMNS and the sensitivity of DNA methylation
testing for screening of unresolved subjects.
In addition to these cases, we ascertained nine subjects
with sequence variants of uncertain significance in six
genes (CHD2, CREBBP, EHMT1, KDM6A, KMT2A, and
PHF6). With the exception of one individual who had a
missense variant in KDM6A (RefSeq NM_021140.2,
c.871G>A, RefSeq NP_066963.2, p.Gly291Arg) and who
represented the DNA methylation profile of Kabuki syn-
drome, all of the others were deemed to be negative for
all of the episignatures described in this study (Table S5),
providing strong functional evidence to rule out these pro-
visional diagnoses (Table S5).
Discussion
Over the past decade, efforts have been made to improve
the diagnostic yield of genetic disorders through means
other than traditional sequence variant assessments.
DNA methylation signatures have gained special interest
through these endeavors, and their assessment in many
syndromes has led to positive and reliable findings.11,40
Compared to the last year, the current study has nearly
doubled the number of conditions that can effectively be
diagnosed through DNA methylation testing.13 Mean-
while, besides improvements in screening and diagnosis,
several repeating patterns are beginning to emerge with re-
gards to DNA methylation signatures in these genetic
syndromes.
After the analysis of 42 syndromes, it can be concluded
that specific peripheral blood episignatures are to be found
in the majority of individuals with congenital syndromes.
The small portion of syndromes with negative findings
may have very mild DNA methylation changes, or they
Figure 6. A Multiclass Classification Al-
gorithm for Concurrent Classification of
34 Episignatures
Concurrent classification of the 34 epis-
ignatures is performed using 34 individual
support vector machine (SVM) classifiers
trained to distinguish each episignature
from all others and from the methylation
profile of the controls. For any given sub-
ject, each of which is represented with a
point here, 34 models will generate 34
scores between 0 and 1 (y axis) representing
the chance that the subject has a methyl-
ation profile similar to each of the 34 epis-
ignatures (x axis). The default cutoff of 0.5
is used for determining the class. However,
most samples received scores close to 0 or
1, and thus for visualization, the points are
jittered. Gray represents samples used in
the training, and blue indicates those that
were not used for training. The top two
panels illustrate samples from the training
and testing dataset with Cornelia de Lange
syndrome (CdLS) and Rubinstein-Taybi
syndrome (RSTS). These two categories
were selectedas examples among the34 cat-
egories due to the challenge presented
earlier in their unsupervised classification
(Figure 5). As seen, each sample has received high scores only for the episignature it is supposed to have, and very low scores for all
others. Samples with RSTS and CdLS have not been classified as one another. The third panel shows a trial performed for a large
cohort of individuals from the general population (n ¼ 2,315) as well as those with other developmental disorders not in the list of our
episignatures (n¼442), all ofwhichare scoredclose to zero.Thefinalpanel illustrates a cohort ofunresolvedsubjects (n¼965)withvarious
congenital anomalies among which a total of nine have been classified as potential cases of some of the syndromes in the study.
The American Journal of Human Genetics 106, 356–370, March 5, 2020 367
may only represent episignatures in certain specific tissues,
or in genetic loci not covered by the Infinium arrays. Some
such syndromes with mild changes will likely eventually
lead to positive findings through reassessment of larger
cohorts, as has occurred for BAFopathies in which our
primary analysis was negative.12 Yet which genetic syn-
dromes are associated with DNA methylation changes re-
mains unpredictable. We do not see a conclusive and
consistent relationship between the gene function or clin-
ical features and the presence of an episignature. There are
several observations that might be worth consideration.
Whenever the gene function involves a direct regulation
of the methylation marks, an extensive level of changes
in the methylome may be expected. Examples include
DNMT1, DNMT3A, and DNMT3B, which encode various
DNA methyltransferases41 and which are associated with
very strong DNA methylation patterns. The observed pat-
terns in these cases are also consistent with their immedi-
ate functionality, including a strong hypomethylation
seen in our study in those with DNMT3A and DNMT3B de-
fects. In other conditions, the changes most likely result
from downstream pathways.10,13,42 The evidence for this
comes from the general trend observed among multiple
genetically heterogeneous conditions in which various
gene defects result in similar episignatures. Most encoded
genes of interest are part of a multi-protein complex or
are key members of a single regulatory pathway. DNMT3B
(ICF1), the only exception to this rule (distinguishable
from ICF2–4), is involved in de novomethylation,43 a func-
tionality that is absent in other ICF-related genes. Other
interesting observations noted on several occasions
throughout the analysis of these syndromes include a
linear relationship between the defective protein dosage
and the intensity of methylation changes, as well as the
symmetrical patterns seen in protein loss versus gain. In
all of these scenarios, the presence of one defective allele
in the absence of clinical presentations was enough for
the detection of DNA methylation changes. Similarly, it
was noted that among X-linked disorders, a skewed X-inac-
tivation may be the cause for concealing an episignature,
as noted in CdLS5, which did not show any methylation
profile. Of note, multiple reports have documented a
skewed inactivation of the X chromosome harboring the
mutated HDAC8 allele in the peripheral blood (but not
some other tissues) of individuals with CdLS5.37 All of
our CdLS5 subjects were females. Due to lack of X inactiva-
tion, male CdLS5 subjects might present a methylation
pattern similar to those of subjects with other CdLS sub-
types; this remains to be studied. These findings will un-
doubtedly pose more questions than answers regarding
the underlying mechanisms of incomplete penetrance in
Mendelian disorders. However, they do provide great po-
tential for carrier screening and confirmation of DNA
sequence variant pathogenicity in healthy carrier individ-
uals with affected offspring.
While the biological interpretation of peripheral blood
episgnatures in congenital disorders remains a daunting
task requiring further experiments and study, their clinical
diagnostic utility is obvious. We have previously demon-
strated the use of episignatures for the classification of sub-
jects with uncertain diagnoses, as well as for screening of
unresolved cohorts using a smaller number of condi-
tions.13 The current study demonstrates that these utilities
can be accurately implemented using the newly mapped
episignatures, although new challenges were introduced
during the process which were not present in the analysis
of a single syndrome or a smaller number of syndromes. As
a general trend, consistent with our previous observations,
we have found that the episignatures remain independent
of each other. In cases where the patterns were mild,
however, there is a chance ofmisclassification of other syn-
dromes with stronger signatures as the first episignature.
This challenge will not be resolved unless the episignatures
of both syndromes are evaluated together, or a supervised
algorithm is trained to distinguish the second episignature.
This is an important observation in this study; it indicates
that the overlap can be a basis for uncertain or incorrect
classifications and that using DNA methylation for disease
classifications should be performed with simultaneous
consideration of all of the mapped episignatures. Through
the development of a supervised algorithm that considers
the methylation patterns of all of the syndromes during
classification, we have shown here that one can avoid
the chance of misclassification due to the closeness of
some of the episignatures. This approach will ensure that
the addition of new episignatures for disease classification
will remain a practical and evolving topic.
Clinical episignature analysis could prove to be an effi-
cient and effective diagnostic tool as part of a typical
first-visit assessment for complex cases presenting with
ambiguous phenotypes. Combined with CNV microarray
and sequence analysis, clinical episignature analysis may
provide higher diagnostic yield in a more efficient manner
than do current standards of care.44 In the last year, our
assessment of a cohort of 965 unresolved individuals
with congenital anomalies and developmental delays
identified 15 individuals with potential diagnoses of 14
syndromes along with more than a dozen individuals
with other locus-specific methylation defects such as
imprinting disorders and trinucleotide repeat expan-
sions.13 Assessment of the same cohort through the use
of the newly discovered episignatures in the current study
has added another nine individuals to this list, represent-
ing an increased diagnostic yield. The success in applying
epigenomics to screening and disease classification in
congenital syndromes is highly contingent upon the map-
ping of DNA methylation episignatures from a large data-
base of syndromes. This growing field will likely tackle
many of the challenges being faced today in medical ge-
netics practice with regards to the diagnosis of congenital
disorders.
These findings demonstrate that the field of clinical and
genetic diagnosis of hereditary disorders is rapidly entering
a new era, i.e., clinical epigenomics. With the growing
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scientific knowledge and expanding clinical utility of DNA
methylation episignatures, it becomes more necessary to
engage expert groups, medical and laboratory regulatory
bodies, and professional colleges in the development of
clinical and laboratory guidelines and recommendations
for an appropriate use of this new post-genomics clinical
testing modality.
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worth, P., Paré, G., Rodenhiser, D., Schwartz, C., and Sadi-
kovic, B. (2017). The defining DNA methylation signature of
Kabuki syndrome enables functional assessment of genetic
variants of unknown clinical significance. Epigenetics 12,
923–933.
18. Aref-Eshghi, E., Bend, E.G., Hood, R.L., Schenkel, L.C., Carere,
D.A., Chakrabarti, R., Nagamani, S.C.S., Cheung, S.W., Cam-
peau, P.M., Prasad, C., et al. (2018). BAFopathies’ DNAmethyl-
ation epi-signatures demonstrate diagnostic utility and func-
tional continuum of Coffin–Siris and Nicolaides–Baraitser
syndromes. Nat. Commun. 9, 4885.
19. Krzyzewska, I.M., Maas, S.M., Henneman, P., Lip, K.V.D., Ven-
ema, A., Baranano, K., Chassevent, A., Aref-Eshghi, E., van Es-
sen, A.J., Fukuda, T., et al. (2019). A genome-wide DNA
methylation signature for SETD1B-related syndrome. Clin.
Epigenetics 11, 156.
20. Ciolfi, A., and Aref-Eshghi, E. (2020). Frameshift mutations at
the C-terminus of HIST1H1E result in a specific DNA hypome-
thylation signature. Clin. Epigenetics 12, 7.
21. Velasco, G., Grillo, G., Touleimat, N., Ferry, L., Ivkovic, I., Ri-
bierre, F., Deleuze, J.F., Chantalat, S., Picard, C., and Francastel,
C. (2018). Comparative methylome analysis of ICF patients
identifies heterochromatin loci that require ZBTB24, CDCA7
and HELLS for their methylated state. Hum. Mol. Genet. 27,
2409–2424.
22. Bjornsson, H.T. (2015). The Mendelian disorders of the epige-
netic machinery. Genome Res. 25, 1473–1481.
23. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster,
J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al.; ACMG
Laboratory Quality Assurance Committee (2015). Standards
and guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet. Med. 17, 405–424.
24. Kular, L., Liu, Y., Ruhrmann, S., Zheleznyakova, G., Marabita,
F., Gomez-Cabrero, D., James, T., Ewing, E., Lindén, M., Górni-
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S.E., Greco, D., Söderhäll, C., Scheynius, A., and Kere, J.
(2012). Differential DNA methylation in purified human
blood cells: implications for cell lineage and studies on disease
susceptibility. PLoS ONE 7, e41361.
37. Deardorff, M.A., Bando, M., Nakato, R., Watrin, E., Itoh, T.,
Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D.,
et al. (2012). HDAC8 mutations in Cornelia de Lange syn-
drome affect the cohesin acetylation cycle. Nature 489,
313–317.
38. Nascimento, R.M., Otto, P.A., de Brouwer, A.P., and Vianna-
Morgante, A.M. (2006). UBE2A, which encodes a ubiquitin-
conjugating enzyme, is mutated in a novel X-linked mental
retardation syndrome. Am. J. Hum. Genet. 79, 549–555.
39. Tan,W.H., Bird, L.M., Thibert, R.L., andWilliams, C.A. (2014).
If not Angelman, what is it? A review of Angelman-like syn-
dromes. Am. J. Med. Genet. A. 164A, 975–992.
40. Aygun, D., and Bjornsson, H.T. (2020). Clinical epigenetics: a
primer for the practitioner. Dev. Med. Child Neurol. 62, 192–
200.
41. Aref-Eshghi, E., Schenkel, L.C., Carere, D.A., Rodenhiser, D.I.,
and Sadikovic, B. (2018). Epigenomic Mechanisms of Human
Developmental Disorders. In Epigenetics in Human Disease,
pp. 837–859.
42. Krzyzewska, I.M., Maas, S.M., Henneman, P., Lip, K.V.D., Ven-
ema, A., Baranano, K., Chassevent, A., Aref-Eshghi, E., van Es-
sen, A.J., Fukuda, T., et al. (2019). A genome-wide DNA
methylation signature for SETD1B-related syndrome. Clin.
Epigenetics 1, 156.
43. Baubec, T., Colombo, D.F., Wirbelauer, C., Schmidt, J., Burger,
L., Krebs, A.R., Akalin, A., and Schübeler, D. (2015). Genomic
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